Full history for every metric is available with a Kvantra account
Kancera AB (publ) (KAN.ST)
Key financial summary
Financials in SEK| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | SEK m | 3 | 0 | 2 | 1 | 1 | 0 | 0 |
| Operating profit | SEK m | -46 | -41 | |||||
| Net profit | SEK m | -36 | -40 | -46 | -52 | -65 | -45 | -40 |
| EPS reported | SEK | -0.39 | -0.33 | |||||
| Operating cashflow per share | SEK | -0.51 | -0.08 | |||||
| Capex per share | SEK | 0.00 | 0.00 | |||||
| FCF per share | SEK | -0.51 | -0.08 | |||||
| Free cash flow | SEK m | -59 | -39 | |||||
| Net debt | SEK m | -46 | -28 | |||||
| Book value equity | SEK m | 62 | 43 | |||||
| Book value per share | SEK | 0.54 | 0.36 | |||||
| Number of shares | m | 115.33 | 121.19 | |||||
| DPS (TTM paid) | SEK | 0.00 | 0.00 |
Financial summary
Financials in SEK| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 2.02 | 0.84 | |||||
| P/S LTM | x | 8,979.42 | 2,575.21 | |||||
| P/FCF LTM | x | -2.15 | -0.91 | |||||
| EV/EBITDA LTM | x | -1.84 | -0.21 | |||||
| EV/Sales LTM | x | 5,667.85 | 603.92 | |||||
| Earnings Yield LTM | % | -35.45% | -53.20% | |||||
| FCF Yield | % | -46.56% | -109.33% | |||||
| Quality | ||||||||
| ROE | % | -71.53% | -41.47% | |||||
| ROIC | % | -74.09% | -45.11% | |||||
| Operating margin | % | -329721.4% | 0.00% | |||||
| Gross margin | % | 100.00% | 0.00% | |||||
| FCF/Sales | % | -418078.6% | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -98.65% | -96.84% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 1.07 | 1.42 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -36.88% | -76.55% | |||||
| Net debt/Equity | x | -0.74 | -0.64 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Kancera AB (publ), a biopharmaceutical firm founded in Solna, Sweden, in 2010, specializes in the development of new treatments for inflammatory disorders and various types of cancer, operating both domestically and internationally. The company's pipeline includes several small molecule drug candidates. KAND567 is presently in a Phase IIa clinical trial, assessing its effectiveness against inflammatory heart disease occurring after a heart attack. Additionally, KAND145 is undergoing a Phase I study with healthy volunteers to establish optimal dosing for cancer therapy, alongside a Phase IIa study specifically targeting ovarian cancer. Kancera's research efforts also encompass HDAC inhibitors for managing nerve inflammation and pain, as well as ROR1 inhibitors for addressing solid tumors and blood-related cancers.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Kancera AB (publ) (KAN.ST)
Kancera AB (publ), a biopharmaceutical firm founded in Solna, Sweden, in 2010, specializes in the development of new treatments for inflammatory disorders and various types of cancer, operating both domestically and internationally. The company's pipeline includes several small molecule drug candidates. KAND567 is presently in a Phase IIa clinical trial, assessing its effectiveness against inflammatory heart disease occurring after a heart attack. Additionally, KAND145 is undergoing a Phase I study with healthy volunteers to establish optimal dosing for cancer therapy, alongside a Phase IIa study specifically targeting ovarian cancer. Kancera's research efforts also encompass HDAC inhibitors for managing nerve inflammation and pain, as well as ROR1 inhibitors for addressing solid tumors and blood-related cancers.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free